SPR Therapeutics

SPR Therapeutics is a privately held medical device company headquartered in Cleveland, Ohio that designs, manufactures and commercializes non-opioid, non-surgical, minimally invasive treatments for acute and chronic pain. Its principal product is the SPRINT Peripheral Nerve Stimulation (PNS) System, an FDA-cleared, percutaneous system in which a thin coiled lead is placed near a targeted nerve and connected to a body-worn stimulator to deliver electrical stimulation for up to 60 days, without a permanent implant. The therapy is positioned for use earlier in the pain care continuum than radiofrequency ablation or permanently implanted neurostimulators, and is applied to low back, shoulder, knee, sacroiliac joint, and head and neck pain.

The company supports the system with a substantial clinical evidence program, including the RESET randomized controlled trial comparing 60-day percutaneous PNS with standard interventional management for chronic low back pain, prospective multicenter studies of medial branch nerve stimulation with four-year follow-up, a sham-controlled study of persistent post-total-knee-arthroplasty pain, the MONARCH case series in occipital neuralgia and cervicogenic headache, and retrospective real-world reviews. A retrospective review of more than 6,100 patients treated with SPRINT reported that over 71 percent showed significant pain relief and/or improvement in quality of life following 60-day treatment. Reported common adverse events include skin irritation and erythema. Internally, SPR runs Rootstock Cloud ERP, ComplianceQuest EQMS and Salesforce CRM on the Salesforce platform to support quality management, inventory, complaint handling and financial reporting.

Founding story

SPR Therapeutics originated from research by Maria Bennett, whose biomedical engineering master's thesis at Case Western Reserve University examined nerve stimulation, rather than surgery or medication, as a viable option for treating chronic pain. That work became the basis for the company she founded in Cleveland; sources give the founding year as 2009 or 2010. Bennett serves as President, CEO and Founder.

Business model

SPR develops, manufactures and commercializes the SPRINT PNS System as a medical device sold for use by physicians treating patients with acute and chronic pain, supported by expanding reimbursement coverage for percutaneous PNS.

Revenue is generated from commercial sales of the SPRINT PNS System through a direct U.S. sales organization; the company reported year-over-year revenue growth of more than 50 percent from 2022 to 2023.

Traction

The SPRINT device has treated more than 50,000 patients. The company reported nearly 200 percent growth of its team over two years and more than 50 percent revenue growth from 2022 to 2023, and it has been recognized among the fastest-growing companies in Greater Cleveland in consecutive years and has won five consecutive Top Workplaces awards.

Latest developments

Medtronic announced on 2026-05-20 its intent to acquire SPR Therapeutics for approximately $650 million in cash for all outstanding equity, with closing expected in the first half of Medtronic's fiscal year 2027 and subject to regulatory approvals. SPR also reports upcoming presentation of three SPRINT PNS abstracts at ASPN 2026 and a publication on sustained benefits in low back pain patients.